Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Exozymes Q3 2026 Results: Net Loss of $2.24M, Loss Narrows

EXOZYMES INC. reported a net loss of $7.49 million for the nine months ended September 30, 2026, compared to a $6.50 million loss in the prior year. The company remains in a development stage with no operating income, primarily funded by a public offering and registered direct offering that raised approximately $5.86 million in net proceeds during the period.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Profit before tax-2.2-2.3
Net income-2.2-2.3
EPS (diluted, $ a share)$-0.24$-0.27

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NASDAQ: EXOZ. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Exozymes Inc.: key numbers

Share price
$3.99Close, Nov 16
Market cap
$37.7M
Shares outstanding
9.44MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Exozymes Inc.

All →
3:01 PM ET Form 4
Insider Selling

Exozymes Chief Commercial Officer Damien Alan Perriman Sells $19.4K of Stock

Damien Alan Perriman, Chief Commercial Officer, sold 3,729 shares of Exozymes Inc. at $5.21 a share, worth $19.4K in total on Oct 12, 2026. Shares held after the trade: 28,692 (-11.5%).

Value
$19.4K
Shares
3,729
Price
$5.21
Role
Chief Commercial Officer
Holding change
-11.5%
Trade date
Oct 12, 2026
12:11 PM ET 8-K
Investor Presentation

Exozymes Investor Presentation

eXoZymes Inc. filed a formal Investor Presentation dated October 6, 2026, to be shared with investment bankers and potential investors. The presentation provides strategic highlights and business updates for the company's current and future stakeholders.

1:25 PM ET 8-K
Shareholder Meeting

Exozymes Shareholder Meeting

Exozymes Inc. has scheduled its 2026 Annual Meeting of Shareholders for November 13, 2026. The company established a record date of September 15, 2026, and plans to distribute proxy materials to shareholders on or about September 28, 2026.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.